Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Local Anesthetics: Common Agents and Their Applications01:23

Local Anesthetics: Common Agents and Their Applications

Local anesthetics (LAs) are commonly used for various applications in medical and dental procedures. Some of the common agents used are cocaine, lidocaine, and bupivacaine.
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

Local Anesthetics: Clinical Application as Epidural Anesthesia

Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modularity and Blended Methodology on Master Education for Donation and Transplantation.

Transplantation proceedingsยท2018
See all related articles

Related Experiment Video

Updated: Jun 29, 2026

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications
13:51

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications

Published on: November 10, 2017

[Lanthanum carbonate in clinical practice].

V Torregrosa Prats1

  • 1Servicio de Nefrologia, Unidad Trasplante Renal, Hospital Clinic, Barcelona, Spain.

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|October 14, 2008
PubMed
Summary

Lanthanum carbonate effectively controls serum phosphate in chronic kidney disease patients for up to 5 years. This phosphate binder is well-tolerated, with rare gastrointestinal issues and no hypercalcemia, improving patient compliance.

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Background:

  • Lanthanum carbonate is a rare earth element studied for intestinal phosphate binding due to low solubility.
  • It is used in monotherapy for managing hyperphosphatemia in chronic kidney disease (CKD).

Purpose of the Study:

  • To evaluate the efficacy and safety of lanthanum carbonate as a phosphate binder.
  • To assess its impact on serum phosphate levels and potential side effects in CKD patients.

Main Methods:

  • Clinical trials were conducted to assess lanthanum carbonate's effectiveness.
  • Adverse effects, drug interactions, and pharmacokinetic profiles were analyzed.

Main Results:

  • Serum phosphate controlled in ~70% of patients at 5 years without hypercalcemia.

More Related Videos

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

Application of Elemental Lanthanides in the Selective C-F Activation of Trifluoromethylated Benzofulvenes Providing Access to Various Difluoroalkenes
10:10

Application of Elemental Lanthanides in the Selective C-F Activation of Trifluoromethylated Benzofulvenes Providing Access to Various Difluoroalkenes

Published on: July 28, 2018

Related Experiment Videos

Last Updated: Jun 29, 2026

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications
13:51

Synthesis of Core-shell Lanthanide-doped Upconversion Nanocrystals for Cellular Applications

Published on: November 10, 2017

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

Application of Elemental Lanthanides in the Selective C-F Activation of Trifluoromethylated Benzofulvenes Providing Access to Various Difluoroalkenes
10:10

Application of Elemental Lanthanides in the Selective C-F Activation of Trifluoromethylated Benzofulvenes Providing Access to Various Difluoroalkenes

Published on: July 28, 2018

  • Low incidence of gastrointestinal disturbances (6%) observed.
  • No significant impact on fat-soluble vitamins or interactions with common medications, except for quinolones, tetracyclines, and doxycycline.
  • Conclusions:

    • Lanthanum carbonate is a potent and well-tolerated phosphate binder for CKD patients.
    • Chewable formulations and reduced daily tablet count may improve patient compliance.
    • Effective phosphate control is achievable with minimal adverse effects.